Meanwhile, Wang et al. reported that a patient with EGFR ex19del-mutated lung adenocarcinoma was initially treated with gefitinib and then osimertinib, followed by disease progression after gaining triple mutation of EGFR ex19del/T790M/cis-C797S, and achieved significant efficacy by using brigatinib in combination with cetuximab (Figs. 3–4) [88]. The gene discussed is EGFR; the disease is lung adenocarcinoma.